| 产品描述: | Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A |
| 靶点: |
Thrombopoietin Receptor |
| 体内研究: |
Avatrombopag (AKR-501) maleate (0.3-3 mg/kg,口服,每天一次,14 天) 以剂量依赖性增加移植了人胎肝 (FL) CD34+ 细胞的非肥胖糖尿病/严重联合免疫缺陷症 (NOD/SCID) 小鼠体内的人血小板数量。 |
| 参考文献: |
1. Fukushima-Shintani M, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247-254. 2. Xu H, et al. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019;12(9):859-865.3. Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952-960. |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.306 ml |
6.53 ml |
13.059 ml |
| 5 mM |
0.261 ml |
1.306 ml |
2.612 ml |
| 10 mM |
0.131 ml |
0.653 ml |
1.306 ml |
| 50 mM |
0.026 ml |
0.131 ml |
0.261 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |